Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.
Authors
- В. В. Петкау (ORCID: https://orcid.org/0000-0002-0342-4007)
- Sufia Safina (ORCID: https://orcid.org/0000-0002-5309-8406)
- R. V. Orlova (ORCID: https://orcid.org/0000-0002-9368-5517)
- Varvara Bragina
- А. S. Kalpinskiy (ORCID: https://orcid.org/0000-0002-2209-3020)
- Alexey Shkurat (ORCID: https://orcid.org/0000-0003-0776-724X)
- Ilya Tsimafeyeu
- Vyacheslav Chubenko
- Р. А. Зуков (ORCID: https://orcid.org/0000-0002-7210-3020)
- Elena Tkacheva (ORCID: https://orcid.org/0000-0003-3651-5359)
- О. В. Бакланова (ORCID: https://orcid.org/0000-0002-1357-3145)
- Elvira Parsadanova (ORCID: https://orcid.org/0009-0001-5470-0219)
- Maria Turganova
- Andrei Lebedinets
- Olga Novikova
- Yulia Anzhiganova
- Natalia Tovbik
Institutions
- St Petersburg University (RU)
- Sakhalin State University (RU)
- Krasnoyarsk State Medical University (RU)
- Leningrad Regional Cancer Center (RU)
- Irkutsk Regional Clinical Hospital (RU)
- Krasnoyarsk Regional Clinical Hospital (RU)
- Republican Oncological Clinical Dispensary (RU)
- P.A. Hertzen Moscow Oncology Research Institute (RU)
- State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care (RU)
Publication Details
- Journal
- Current Oncology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.3390/curroncol32010011
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26